Summary of Castle Biosciences Q4 and Full Year 2025 Earnings Call

1Key Financial Results and Metrics

Q4 2025 Revenue: $87.0 million

Full Year 2025 Revenue: $344.2 million, exceeding guidance.

Test Report Volume: 105,053 reports for 2025, a 37% increase year-over-year.

Adjusted Gross Margin: 79.8% for 2025, down from 82% in 2024.

Net Loss: $24.2 million for 2025, compared to net income of $18.2 million in 2024.

Diluted Loss per Share: $0.83 for 2025, compared to earnings of $0.62 in 2024.

Adjusted EBITDA: $44 million for 2025, down from $75 million in 2024.

Cash Position: $299.5 million in cash, cash equivalents, and marketable securities as of December 31, 2025.

2Strategic Updates and Business Highlights

Core Revenue Drivers: Continued momentum in DecisionDx-Melanoma and TissueCypher, with the latter achieving 86% growth in test reports.

Acquisitions and Collaborations: Completed acquisition of Previse and entered a collaboration with SciBase to enhance product offerings.

New Product Launch: Launched AdvanceAD-Tx, a test for atopic dermatitis, with initial positive uptake from dermatological accounts.

Clinical Evidence: DecisionDx-Melanoma surpassed 230,000 test orders, supported by 58 peer-reviewed publications.

3Forward Guidance and Outlook

2026 Revenue Guidance: Expected revenue between $340 million and $350 million, representing mid- to high-teens growth excluding certain revenues.

Volume Growth Expectations: Anticipate continued growth in DecisionDx-Melanoma and TissueCypher, with mid- to high single-digit growth for melanoma tests.

AdvanceAD-Tx: Expected to contribute immaterial revenue in 2026, with more significant contributions anticipated in 2027 or 2028.

4Bad News, Challenges, or Points of Concern

Declining Metrics: Significant net loss in 2025 compared to a profit in 2024, and a drop in adjusted EBITDA.

Gross Margin Pressure: Decrease in gross margin due to the loss of revenue from DecisionDx-SCC and increased operating expenses.

Regulatory Risks: Uncertainty regarding FDA approval timelines for DecisionDx-Melanoma and potential impacts on reimbursement discussions.

Market Competition: Concerns about the NCCN guidelines not including all relevant studies for DecisionDx-Melanoma, which may affect adoption.

5Notable Q&A Insights

NCCN Guidelines: Discussion on the lack of acknowledgment for DecisionDx-Melanoma in recent NCCN updates, despite substantial clinical evidence.

Sales Strategy for AdvanceAD-Tx: Focus on maintaining momentum with DecisionDx-Melanoma while gradually introducing AdvanceAD-Tx to dermatologists.

Sales Force Expansion: Plans to continue expanding the sales team for TissueCypher and dermatology, with a target of fewer than 100 reps for effective management.

Market Penetration: Current clinician penetration for TissueCypher is about 11%, indicating significant room for growth. This summary encapsulates Castle Biosciences' performance and strategic direction, highlighting both achievements and challenges as they navigate the evolving landscape of diagnostic testing.